Skip to main content
Top
Published in: Breast Cancer Research 1/2016

Open Access 01-12-2016 | Research article

Genetic predisposition to ductal carcinoma in situ of the breast

Authors: Christos Petridis, Mark N. Brook, Vandna Shah, Kelly Kohut, Patricia Gorman, Michele Caneppele, Dina Levi, Efterpi Papouli, Nick Orr, Angela Cox, Simon S. Cross, Isabel dos-Santos-Silva, Julian Peto, Anthony Swerdlow, Minouk J. Schoemaker, Manjeet K. Bolla, Qin Wang, Joe Dennis, Kyriaki Michailidou, Javier Benitez, Anna González-Neira, Daniel C. Tessier, Daniel Vincent, Jingmei Li, Jonine Figueroa, Vessela Kristensen, Anne-Lise Borresen-Dale, Penny Soucy, Jacques Simard, Roger L. Milne, Graham G. Giles, Sara Margolin, Annika Lindblom, Thomas Brüning, Hiltrud Brauch, Melissa C. Southey, John L. Hopper, Thilo Dörk, Natalia V. Bogdanova, Maria Kabisch, Ute Hamann, Rita K. Schmutzler, Alfons Meindl, Hermann Brenner, Volker Arndt, Robert Winqvist, Katri Pylkäs, Peter A. Fasching, Matthias W. Beckmann, Jan Lubinski, Anna Jakubowska, Anna Marie Mulligan, Irene L. Andrulis, Rob A. E. M. Tollenaar, Peter Devilee, Loic Le Marchand, Christopher A. Haiman, Arto Mannermaa, Veli-Matti Kosma, Paolo Radice, Paolo Peterlongo, Frederik Marme, Barbara Burwinkel, Carolien H. M. van Deurzen, Antoinette Hollestelle, Nicola Miller, Michael J. Kerin, Diether Lambrechts, Giuseppe Floris, Jelle Wesseling, Henrik Flyger, Stig E. Bojesen, Song Yao, Christine B. Ambrosone, Georgia Chenevix-Trench, Thérèse Truong, Pascal Guénel, Anja Rudolph, Jenny Chang-Claude, Heli Nevanlinna, Carl Blomqvist, Kamila Czene, Judith S. Brand, Janet E. Olson, Fergus J. Couch, Alison M. Dunning, Per Hall, Douglas F. Easton, Paul D. P. Pharoah, Sarah E. Pinder, Marjanka K Schmidt, Ian Tomlinson, Rebecca Roylance, Montserrat García-Closas, Elinor J. Sawyer

Published in: Breast Cancer Research | Issue 1/2016

Login to get access

Abstract

Background

Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer. It is often associated with invasive ductal carcinoma (IDC), and is considered to be a non-obligate precursor of IDC. It is not clear to what extent these two forms of cancer share low-risk susceptibility loci, or whether there are differences in the strength of association for shared loci.

Methods

To identify genetic polymorphisms that predispose to DCIS, we pooled data from 38 studies comprising 5,067 cases of DCIS, 24,584 cases of IDC and 37,467 controls, all genotyped using the iCOGS chip.

Results

Most (67 %) of the 76 known breast cancer predisposition loci showed an association with DCIS in the same direction as previously reported for invasive breast cancer. Case-only analysis showed no evidence for differences between associations for IDC and DCIS after considering multiple testing.
Analysis by estrogen receptor (ER) status confirmed that loci associated with ER positive IDC were also associated with ER positive DCIS. Analysis of DCIS by grade suggested that two independent SNPs at 11q13.3 near CCND1 were specific to low/intermediate grade DCIS (rs75915166, rs554219). These associations with grade remained after adjusting for ER status and were also found in IDC.
We found no novel DCIS-specific loci at a genome wide significance level of P < 5.0x10-8.

Conclusion

In conclusion, this study provides the strongest evidence to date of a shared genetic susceptibility for IDC and DCIS. Studies with larger numbers of DCIS are needed to determine if IDC or DCIS specific loci exist.
Appendix
Available only for authorised users
Literature
1.
go back to reference Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to. Cancer Epidemiol Biomarkers Prev. 2001;14(4):1008–11.CrossRef Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to. Cancer Epidemiol Biomarkers Prev. 2001;14(4):1008–11.CrossRef
2.
go back to reference Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004;96(12):906–20.CrossRefPubMed Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004;96(12):906–20.CrossRefPubMed
3.
go back to reference Wong H, Lau S, Yau T, Cheung P, Epstein RJ. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Brit J Cancer. 2010;102(9):1391–6.CrossRefPubMedPubMedCentral Wong H, Lau S, Yau T, Cheung P, Epstein RJ. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Brit J Cancer. 2010;102(9):1391–6.CrossRefPubMedPubMedCentral
4.
5.
go back to reference Li CI, Malone KE, Saltzman BS, Daling JR. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer. 2006;106(10):2104–12.CrossRefPubMed Li CI, Malone KE, Saltzman BS, Daling JR. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer. 2006;106(10):2104–12.CrossRefPubMed
6.
go back to reference Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses’ Health Study. Cancer. 2005;103(9):1778–84.CrossRefPubMed Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses’ Health Study. Cancer. 2005;103(9):1778–84.CrossRefPubMed
7.
go back to reference Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478–88.CrossRefPubMedPubMedCentral Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478–88.CrossRefPubMedPubMedCentral
8.
go back to reference Pinder SE. Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation. Mod Pathol. 2010;23 Suppl 2:S8–13.CrossRefPubMed Pinder SE. Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation. Mod Pathol. 2010;23 Suppl 2:S8–13.CrossRefPubMed
9.
go back to reference Aguiar FN, Mendes HN, Bacchi CE, Carvalho FM. Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast. Rev Bras Ginecol Obstet. 2013;35(3):97–102.CrossRefPubMed Aguiar FN, Mendes HN, Bacchi CE, Carvalho FM. Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast. Rev Bras Ginecol Obstet. 2013;35(3):97–102.CrossRefPubMed
10.
go back to reference Leong AS, Sormunen RT, Vinyuvat S, Hamdani RW, Suthipintawong C. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems. Am J Clin Pathol. 2001;115(5):709–18.CrossRefPubMed Leong AS, Sormunen RT, Vinyuvat S, Hamdani RW, Suthipintawong C. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems. Am J Clin Pathol. 2001;115(5):709–18.CrossRefPubMed
11.
go back to reference Claus EB, Stowe M, Carter D. Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst. 2001;93(23):1811–7.CrossRefPubMed Claus EB, Stowe M, Carter D. Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst. 2001;93(23):1811–7.CrossRefPubMed
12.
go back to reference Reeves GK, Pirie K, Green J, Bull D, Beral V, Million Women Study C. Comparison of the effects of genetic and environmental risk factors on in situ and invasive ductal breast cancer. Int J Cancer. 2012;131(4):930–7.CrossRefPubMed Reeves GK, Pirie K, Green J, Bull D, Beral V, Million Women Study C. Comparison of the effects of genetic and environmental risk factors on in situ and invasive ductal breast cancer. Int J Cancer. 2012;131(4):930–7.CrossRefPubMed
13.
go back to reference Claus EB, Stowe M, Carter D. Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. Breast Cancer Res Treat. 2003;78(1):7–15.CrossRefPubMed Claus EB, Stowe M, Carter D. Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. Breast Cancer Res Treat. 2003;78(1):7–15.CrossRefPubMed
14.
go back to reference Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst. 1997;89(1):76–82.CrossRefPubMed Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst. 1997;89(1):76–82.CrossRefPubMed
15.
go back to reference Claus EB, Petruzella S, Matloff E, Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA. 2005;293(8):964–9.CrossRefPubMed Claus EB, Petruzella S, Matloff E, Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA. 2005;293(8):964–9.CrossRefPubMed
16.
go back to reference Sawyer E, Roylance R, Petridis C, Brook MN, Nowinski S, Papouli E, et al. Genetic predisposition to in situ and invasive lobular carcinoma of the breast. PLoS Genet. 2014;10(4):e1004285.CrossRefPubMedPubMedCentral Sawyer E, Roylance R, Petridis C, Brook MN, Nowinski S, Papouli E, et al. Genetic predisposition to in situ and invasive lobular carcinoma of the breast. PLoS Genet. 2014;10(4):e1004285.CrossRefPubMedPubMedCentral
17.
go back to reference Purrington KS, Slager S, Eccles D, Yannoukakos D, Fasching PA, Miron P, et al. Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis. 2014;35(5):1012–9.CrossRefPubMed Purrington KS, Slager S, Eccles D, Yannoukakos D, Fasching PA, Miron P, et al. Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis. 2014;35(5):1012–9.CrossRefPubMed
18.
go back to reference Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 2013;45(4):392–8. 398e391-392.CrossRefPubMedPubMedCentral Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 2013;45(4):392–8. 398e391-392.CrossRefPubMedPubMedCentral
19.
go back to reference Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45(4):353–61. 361e351-352.CrossRefPubMedPubMedCentral Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45(4):353–61. 361e351-352.CrossRefPubMedPubMedCentral
20.
21.
go back to reference Siddiq A, Couch FJ, Chen GK, Lindstrom S, Eccles D, Millikan RC, et al. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet. 2012;21(24):5373–84.CrossRefPubMedPubMedCentral Siddiq A, Couch FJ, Chen GK, Lindstrom S, Eccles D, Millikan RC, et al. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet. 2012;21(24):5373–84.CrossRefPubMedPubMedCentral
22.
go back to reference Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, et al. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med. 2009;133(1):15–25.PubMed Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, et al. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med. 2009;133(1):15–25.PubMed
23.
go back to reference Milne RL, Goode EL, Garca-Closas M, Couch FJ, Severi G, Hein R, et al. Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2222–31.CrossRefPubMedPubMedCentral Milne RL, Goode EL, Garca-Closas M, Couch FJ, Severi G, Hein R, et al. Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2222–31.CrossRefPubMedPubMedCentral
24.
go back to reference Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447(7148):1087–93.CrossRefPubMedPubMedCentral Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447(7148):1087–93.CrossRefPubMedPubMedCentral
25.
go back to reference Campa D, Barrdahl M, Gaudet MM, Black A, Chanock SJ, Diver WR, et al. Genetic risk variants associated with in situ breast cancer. Breast Cancer Res. 2015;17:82.CrossRefPubMedPubMedCentral Campa D, Barrdahl M, Gaudet MM, Black A, Chanock SJ, Diver WR, et al. Genetic risk variants associated with in situ breast cancer. Breast Cancer Res. 2015;17:82.CrossRefPubMedPubMedCentral
26.
go back to reference Milne RL, Burwinkel B, Michailidou K, Arias-Perez JI, Zamora MP, Menendez-Rodriguez P, et al. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2014;23(22):6096–111.CrossRefPubMedPubMedCentral Milne RL, Burwinkel B, Michailidou K, Arias-Perez JI, Zamora MP, Menendez-Rodriguez P, et al. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2014;23(22):6096–111.CrossRefPubMedPubMedCentral
27.
go back to reference Thomas J, Hanby A, Pinder S, Ellis I, Macartney J, Clements K, et al. Implications of inconsistent measurement of ER status in non-invasive breast cancer: a study of 1,684 cases from the Sloane Project. Breast J. 2008;14(1):33–8.CrossRefPubMed Thomas J, Hanby A, Pinder S, Ellis I, Macartney J, Clements K, et al. Implications of inconsistent measurement of ER status in non-invasive breast cancer: a study of 1,684 cases from the Sloane Project. Breast J. 2008;14(1):33–8.CrossRefPubMed
28.
go back to reference Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet. 2008;4(4):e1000054.CrossRefPubMedPubMedCentral Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet. 2008;4(4):e1000054.CrossRefPubMedPubMedCentral
29.
go back to reference Purrington KS, Slettedahl S, Bolla MK, Michailidou K, Czene K, Nevanlinna H, et al. Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Hum Mol Genet. 2014;23(22):6034–46.CrossRefPubMedPubMedCentral Purrington KS, Slettedahl S, Bolla MK, Michailidou K, Czene K, Nevanlinna H, et al. Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Hum Mol Genet. 2014;23(22):6034–46.CrossRefPubMedPubMedCentral
30.
go back to reference Lambrechts D, Truong T, Justenhoven C, Humphreys MK, Wang J, Hopper JL, et al. 11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat. 2012;33(7):1123–32.CrossRefPubMedPubMedCentral Lambrechts D, Truong T, Justenhoven C, Humphreys MK, Wang J, Hopper JL, et al. 11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat. 2012;33(7):1123–32.CrossRefPubMedPubMedCentral
31.
go back to reference French JD, Ghoussaini M, Edwards SL, Meyer KB, Michailidou K, Ahmed S, et al. Functional variants at the 11q13 risk locus for breast cancer regulate Cyclin D1 expression through long-range enhancers. Am J Hum Genet. 2013;92(4):489–503.CrossRefPubMedPubMedCentral French JD, Ghoussaini M, Edwards SL, Meyer KB, Michailidou K, Ahmed S, et al. Functional variants at the 11q13 risk locus for breast cancer regulate Cyclin D1 expression through long-range enhancers. Am J Hum Genet. 2013;92(4):489–503.CrossRefPubMedPubMedCentral
32.
go back to reference Arvold ND, Punglia RS, Hughes ME, Jiang W, Edge SB, Javid SH, et al. Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ. Cancer. 2012;118(24):6022–30.CrossRefPubMedPubMedCentral Arvold ND, Punglia RS, Hughes ME, Jiang W, Edge SB, Javid SH, et al. Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ. Cancer. 2012;118(24):6022–30.CrossRefPubMedPubMedCentral
Metadata
Title
Genetic predisposition to ductal carcinoma in situ of the breast
Authors
Christos Petridis
Mark N. Brook
Vandna Shah
Kelly Kohut
Patricia Gorman
Michele Caneppele
Dina Levi
Efterpi Papouli
Nick Orr
Angela Cox
Simon S. Cross
Isabel dos-Santos-Silva
Julian Peto
Anthony Swerdlow
Minouk J. Schoemaker
Manjeet K. Bolla
Qin Wang
Joe Dennis
Kyriaki Michailidou
Javier Benitez
Anna González-Neira
Daniel C. Tessier
Daniel Vincent
Jingmei Li
Jonine Figueroa
Vessela Kristensen
Anne-Lise Borresen-Dale
Penny Soucy
Jacques Simard
Roger L. Milne
Graham G. Giles
Sara Margolin
Annika Lindblom
Thomas Brüning
Hiltrud Brauch
Melissa C. Southey
John L. Hopper
Thilo Dörk
Natalia V. Bogdanova
Maria Kabisch
Ute Hamann
Rita K. Schmutzler
Alfons Meindl
Hermann Brenner
Volker Arndt
Robert Winqvist
Katri Pylkäs
Peter A. Fasching
Matthias W. Beckmann
Jan Lubinski
Anna Jakubowska
Anna Marie Mulligan
Irene L. Andrulis
Rob A. E. M. Tollenaar
Peter Devilee
Loic Le Marchand
Christopher A. Haiman
Arto Mannermaa
Veli-Matti Kosma
Paolo Radice
Paolo Peterlongo
Frederik Marme
Barbara Burwinkel
Carolien H. M. van Deurzen
Antoinette Hollestelle
Nicola Miller
Michael J. Kerin
Diether Lambrechts
Giuseppe Floris
Jelle Wesseling
Henrik Flyger
Stig E. Bojesen
Song Yao
Christine B. Ambrosone
Georgia Chenevix-Trench
Thérèse Truong
Pascal Guénel
Anja Rudolph
Jenny Chang-Claude
Heli Nevanlinna
Carl Blomqvist
Kamila Czene
Judith S. Brand
Janet E. Olson
Fergus J. Couch
Alison M. Dunning
Per Hall
Douglas F. Easton
Paul D. P. Pharoah
Sarah E. Pinder
Marjanka K Schmidt
Ian Tomlinson
Rebecca Roylance
Montserrat García-Closas
Elinor J. Sawyer
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2016
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-016-0675-7

Other articles of this Issue 1/2016

Breast Cancer Research 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine